Eerulli ennai for childhood asthma

Clinical evaluvation of eerulli ennai (a siddha drug) in the treatment of suzhi mantham (childhood asthma) in children

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/04/008324

Enrollment

Registered

2017-04-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Children of the age group 1 to 3 years with symptoms of: Wheezing Dyspnoea Intermittent fever Indrawing of respiratory muscles Insomnia, Hiccough, Refuse the feeding

Interventions

Intervention1: EERULLI ENNAI: EERULLI ENNAI is a polyherbal formulation 1mlbd 1 to 3 years oral route 1 day Control Intervention1: NOT APPLICABLE: NOT APPLICABLE

Eligibility

Inclusion criteria

Inclusion criteria: Children of the age group 1 to 3 years with symptoms of: Wheezing, Dyspnoea Intermittent fever Indrawing of respiratory muscles Insomnia, Hiccough, Refuse the feeding Willing to sign the informed consent form

Exclusion criteria

Exclusion criteria: Jaundice, Long term fever, Active primary complex Congenital heart diseases Any other serious illness

Design outcomes

Primary

Measure	Time frame
Reduction in episodes of wheezing is assessed by modified CAS asthma score.Timepoint: 5 days	—

Secondary

Measure	Time frame
clinical efficacy of the trail drug and its side effects if anyTimepoint: 15 days	—

Countries

India

Contacts

Public ContactDr A M Amala Hazel

National institute of siddha

mmssiddha@rediffmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026